Sun Pharmaceutical Industries Limited , India's largest pharmaceutical company, has announced the commercial availability of UNLOXCYT™ (cosibelimab-ipdl) in the United States for treating advanced cutaneous squamous cell carcinoma (aCSCC). This milestone represents a significant advancement from the company's earlier plans to launch the treatment in the second half of FY '26.

UNLOXCYT Commercial Launch

UNLOXCYT is now available for healthcare professionals to prescribe for adults with metastatic cutaneous squamous cell carcinoma (mCSCC) or locally advanced CSCC (laCSCC) who are not candidates for curative surgery or curative radiation. The treatment is distributed through a limited network of authorized specialty distributors and one contracted specialty pharmacy.

Clinical Efficacy and Safety Profile

The FDA recently approved an updated label for UNLOXCYT reflecting long-term follow-up data from the pivotal CK-301-101 clinical trial. The treatment demonstrates significant clinical benefits:

The safety profile shows manageable adverse reactions, with the most common being fatigue, musculoskeletal pain, rash, diarrhea, and hypothyroidism. Notably, no patients developed Grade 3 or 4 pneumonitis, with only 0.90% experiencing Grade 2 pneumonitis.

Strong Q1 Financial Performance

Sun Pharma's robust financial foundation supports this launch, with impressive results for the quarter ending June 30:

Market Segment Performance

The company's diversified portfolio shows strong performance across key markets:

India Formulations

Sales grew 13.90% to ₹47,211.00 million, representing 34.20% of total consolidated sales. Sun Pharma maintained its No. 1 ranking in the Indian pharmaceutical market with an 8.30% market share.

US Formulations

US sales reached $473.00 million, contributing 29.30% to total consolidated sales, providing a strong foundation for the UNLOXCYT launch.

Global Innovative Medicines

This segment achieved $311.00 million in sales, up 16.90% year-over-year, representing 19.30% of Q1 sales. UNLOXCYT will further strengthen this high-growth portfolio.

Management Perspective

Richard Ascroft, CEO of Sun Pharma North America, emphasized the treatment's significance: "UNLOXCYT is an evolution in checkpoint inhibition, combining durable efficacy with a proven tolerability profile for a group of aCSCC patients who traditionally would struggle to strike that therapeutic balance."

Dilip Shanghvi, Chairman and Managing Director, highlighted the company's strong quarterly performance: "Sun had a strong performance during the quarter, where the overall growth reflects steady progress across all our markets."

Market Impact and Future Outlook

With an estimated 40,000 US patients progressing to advanced CSCC annually, resulting in nearly 15,000 deaths, UNLOXCYT addresses a significant unmet medical need. The treatment's availability through the UNLOXCYT SUPPORT™ program ensures comprehensive patient access and affordability support.

Sun Pharma's successful launch of UNLOXCYT, combined with its strong financial performance and robust R&D pipeline of six novel entities in clinical stages, positions the company for continued growth in the competitive oncology market.